352 related articles for article (PubMed ID: 15882725)
1. Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer.
de Vries SH; Raaijmakers R; Blijenberg BG; Mikolajczyk SD; Rittenhouse HG; Schröder FH
Urology; 2005 May; 65(5):926-30. PubMed ID: 15882725
[TBL] [Abstract][Full Text] [Related]
2. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.
Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
Urology; 2004 Mar; 63(3):492-8. PubMed ID: 15028444
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
[TBL] [Abstract][Full Text] [Related]
4. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer.
Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
Urol Oncol; 2005; 23(1):16-21. PubMed ID: 15885578
[TBL] [Abstract][Full Text] [Related]
6. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
7. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
8. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
Mikolajczyk SD; Rittenhouse HG
Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
[TBL] [Abstract][Full Text] [Related]
9. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue.
Mikolajczyk SD; Millar LS; Wang TJ; Rittenhouse HG; Marks LS; Song W; Wheeler TM; Slawin KM
Cancer Res; 2000 Feb; 60(3):756-9. PubMed ID: 10676664
[TBL] [Abstract][Full Text] [Related]
10. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum.
Mikolajczyk SD; Grauer LS; Millar LS; Hill TM; Kumar A; Rittenhouse HG; Wolfert RL; Saedi MS
Urology; 1997 Nov; 50(5):710-4. PubMed ID: 9372880
[TBL] [Abstract][Full Text] [Related]
11. Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project.
Pelzer AE; Tewari A; Bektic J; Berger AP; Frauscher F; Bartsch G; Horninger W
Urology; 2005 Nov; 66(5):1029-33. PubMed ID: 16286118
[TBL] [Abstract][Full Text] [Related]
12. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
13. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
Stephan C; Lein M; Jung K; Schnorr D; Loening SA
Cancer; 1997 Jan; 79(1):104-9. PubMed ID: 8988733
[TBL] [Abstract][Full Text] [Related]
14. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
[TBL] [Abstract][Full Text] [Related]
15. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
[TBL] [Abstract][Full Text] [Related]
16. [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy].
Shao Q; Song J; Zhou ZJ; Du LD
Zhonghua Nan Ke Xue; 2008 Jul; 14(7):597-601. PubMed ID: 18686378
[TBL] [Abstract][Full Text] [Related]
17. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
[TBL] [Abstract][Full Text] [Related]
18. Pro PSA : a "pro cancer" form of PSA?
Peyromaure M; Fulla Y; Debré B; Dinh-Xuan AT
Med Hypotheses; 2005; 64(1):92-5. PubMed ID: 15533620
[TBL] [Abstract][Full Text] [Related]
19. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer.
Mikolajczyk SD; Marker KM; Millar LS; Kumar A; Saedi MS; Payne JK; Evans CL; Gasior CL; Linton HJ; Carpenter P; Rittenhouse HG
Cancer Res; 2001 Sep; 61(18):6958-63. PubMed ID: 11559576
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
Andriole GL; Marberger M; Roehrborn CG
J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
